iRhythm Technologies, Inc., a San Francisco, CA-based medical device, service and technology company that develops and markets diagnostic monitoring solutions, closed a $16m Series D venture financing.
The round was led by Norwest Venture Partners (NVP), with participation from existing investors New Leaf Ventures, Synergy Life Science Partners and Kaiser Permanente Ventures.
The company intends to use the capital to fund commercial expansion and accelerate the development of new technologies and applications.
Led by Kevin King, president and CEO, iRhythm provides diagnostic monitoring solutions that facilitate early diagnosis and treatment decisions. Its flagship product, the Zio® Patch, is designed to optimize and simplify the diagnosis of cardiac arrhythmias.